{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/BNTX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-18T16:18:43.408Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4425,"canonical_name":"BioNTech SE","cik":"0001776985","uei":null,"lei":null,"duns":null,"ticker":"BNTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":41,"clinical":9},"count":50,"timeline":[{"ts":"2026-10-13","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-10-13","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000067","accession_number":"0001776985-26-000067","importance":30},{"ts":"2026-10-09","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-10-09","url_slug":"/sec/cik-0001776985/4/0002123975-26-000035","accession_number":"0002123975-26-000035","importance":30},{"ts":"2026-10-07","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-10-07","url_slug":"/sec/cik-0001776985/4/0002123975-26-000033","accession_number":"0002123975-26-000033","importance":30},{"ts":"2026-10-06","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-10-06","url_slug":"/sec/cik-0001776985/4/0002123975-26-000031","accession_number":"0002123975-26-000031","importance":30},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-10-02","url_slug":"/sec/cik-0001776985/4/0002123975-26-000029","accession_number":"0002123975-26-000029","importance":30},{"ts":"2026-09-30","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-30","url_slug":"/sec/cik-0001776985/4/0002123975-26-000027","accession_number":"0002123975-26-000027","importance":30},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Study of COVID-19 Vaccine(s) in Children and Adults","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07798648","excerpt":"[\"COVID-19 Vaccines\"]","importance":60},{"ts":"2026-09-28","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-28","url_slug":"/sec/cik-0001776985/4/0002123975-26-000025","accession_number":"0002123975-26-000025","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-24","url_slug":"/sec/cik-0001776985/4/0002123975-26-000023","accession_number":"0002123975-26-000023","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-22","url_slug":"/sec/cik-0001776985/4/0002123975-26-000021","accession_number":"0002123975-26-000021","importance":30},{"ts":"2026-09-18","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-18","url_slug":"/sec/cik-0001776985/4/0002123975-26-000019","accession_number":"0002123975-26-000019","importance":30},{"ts":"2026-09-18","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-09-18","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000065","accession_number":"0001776985-26-000065","importance":30},{"ts":"2026-09-16","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-16","url_slug":"/sec/cik-0001776985/4/0002123975-26-000017","accession_number":"0002123975-26-000017","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-14","url_slug":"/sec/cik-0001776985/4/0002123975-26-000015","accession_number":"0002123975-26-000015","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-09-14","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000063","accession_number":"0001776985-26-000063","importance":30},{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-11","url_slug":"/sec/cik-0001776985/4/0002123975-26-000013","accession_number":"0002123975-26-000013","importance":30},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Sahin Ugur","title":"Chief Executive Officer","shares":20500,"price_per_share":96.3067,"usd_value":1974287,"security_title":"Ordinary Shares","importance":36.97428735},{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-09","url_slug":"/sec/cik-0001776985/4/0002123975-26-000011","accession_number":"0002123975-26-000011","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-08","url_slug":"/sec/cik-0001776985/4/0002123975-26-000008","accession_number":"0002123975-26-000008","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"144","title":"144 — BioNTech SE — 2026-09-03","url_slug":"/sec/cik-0001776985/144/0002085929-26-000012","accession_number":"0002085929-26-000012","importance":30},{"ts":"2026-08-28","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-08-28","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000061","accession_number":"0001776985-26-000061","importance":30},{"ts":"2026-08-27","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-08-27","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000059","accession_number":"0001776985-26-000059","importance":30},{"ts":"2026-08-21","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07698600","excerpt":"[\"HIV -1 Infection\"]","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-08-20","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000057","accession_number":"0001776985-26-000057","importance":30},{"ts":"2026-08-07","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT07730450","excerpt":"[\"COVID-19 Vaccines\"]","importance":25},{"ts":"2026-08-04","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-08-04","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000054","accession_number":"0001776985-26-000054","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-08-04","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000055","accession_number":"0001776985-26-000055","importance":30},{"ts":"2026-08-03","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-08-03","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000051","accession_number":"0001776985-26-000051","importance":30},{"ts":"2026-07-30","kind":"sec.filing","form_type":"20-F/A","title":"20-F/A — BioNTech SE — 2026-07-30","url_slug":"/sec/cik-0001776985/20-f-a/0001776985-26-000049","accession_number":"0001776985-26-000049","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-07-29","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000047","accession_number":"0001776985-26-000047","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"3","title":"3 — BioNTech SE — 2026-06-26","url_slug":"/sec/cik-0001776985/3/0001938363-26-000006","accession_number":"0001938363-26-000006","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"3","title":"3 — BioNTech SE — 2026-06-26","url_slug":"/sec/cik-0001776985/3/0002138283-26-000002","accession_number":"0002138283-26-000002","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-06-08","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000041","accession_number":"0001776985-26-000041","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-06-01","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000039","accession_number":"0001776985-26-000039","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06827236","excerpt":"[\"Locally Advanced Breast Cancer\",\"Unresectable Breast Carcinoma\",\"Metastatic Breast Cancer\"]","importance":45},{"ts":"2026-05-15","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-05-15","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000035","accession_number":"0001776985-26-000035","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — BioNTech SE — 2026-05-15","url_slug":"/sec/cik-0001776985/schedule-13g-a/0002123975-26-000006","accession_number":"0002123975-26-000006","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04486378","excerpt":"[\"Colorectal Cancer Stage II\",\"Colorectal Cancer Stage III\"]","importance":45},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"BioNTech SE","title":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07455734","excerpt":"[\"Advanced Solid Tumor Cancer\"]","importance":45},{"ts":"2026-05-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — BioNTech SE — 2026-05-14","url_slug":"/sec/cik-0001776985/schedule-13g-a/0002085929-26-000009","accession_number":"0002085929-26-000009","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0001955589-26-000004","accession_number":"0001955589-26-000004","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0002118987-26-000002","accession_number":"0002118987-26-000002","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0002123964-26-000006","accession_number":"0002123964-26-000006","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0002123971-26-000004","accession_number":"0002123971-26-000004","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0002123980-26-000005","accession_number":"0002123980-26-000005","importance":30},{"ts":"2026-05-12","kind":"sec.form144","reporter":"Medine GmbH","title":"Officer, 10% Stockholder","shares":858209,"usd_value":80379855,"security_title":"American Depositary Shares representing ordinary shares, no par value per share","approx_sale_date":"2026-05-13","accession_number":"0002056296-26-000003","importance":56.075970987999995},{"ts":"2026-05-12","kind":"sec.filing","form_type":"144","title":"144 — BioNTech SE — 2026-05-12","url_slug":"/sec/cik-0001776985/144/0002056296-26-000003","accession_number":"0002056296-26-000003","importance":30},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"BioNTech SE","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07173751","excerpt":"[\"Breast Neoplasms\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07255404","excerpt":"[\"Pancreatic Ductal Adenocarcinoma (PDAC)\"]","importance":45},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"BioNTech SE","title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06841055","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":45}]}